Friday, September 08, 2023

New AI Tool designs Cancer combination Drugs using self-combine into nanoparticles To Optimize Treatment

Good news! Cancer is history (soon)!

Sounds like a great approach!

"Scientists at the Technion – Israel Institute of Technology have found drugs that are not only more powerful against tumors when combined, but that also chemically self-combine their nanoparticles to produce an even greater effect.

The resulting nanomedicines are highly effective at targeting cancer cells and fighting tumors, while being less toxic to the patient and causing fewer side effects. 

The researchers have developed an AI that predicts which drug duos can chemically self-assemble or join together to form nanoparticles.

It does so by gathering information about biological synergy from published articles, compiling the pairs of drugs into a comprehensive database, and then pairs drugs based on their potential to create nanoparticles together. 

The AI has proposed 1,985 drug combinations for 70 types of cancer thus far. 

One example of the model’s abilities is a highly effective drug pair for treating head and neck cancer that it discovered. The two drugs, Bortezomib and Cabozantinib, are already approved for cancer treatment – the former for blood cancers, and the latter for liver, kidney, and thyroid cancers. The combination of the two was proven effective and produced fewer side effects than using either of the drugs individually. ..."

"... group has taken this idea to the next level by identifying pairs of drugs that do more than work together biologically to attack the tumor. They also chemically assemble into combined nanoparticles. The researchers describe this synergy of synergies as “meta-synergy,” a cooperative interaction that produces a greater combined effect beyond standard synergy. The resulting nanomedicines are particularly effective at targeting cancer cells and highly successful in fighting tumors, while being less toxic to the patient and causing fewer side effects. ..."

New AI Tool Combines Cancer Drugs To Optimize Treatment

No comments: